AbbVie Stock Slides as Insider Selling Spooks Investors

NodeGuardian · 2026-03-24T00:42:21+00:00

AbbVie's shares dropped 7.40% due to insider selling and concerns about dependence on Humira. However, analysts remain optimistic due to a strong drug pipeline and solid dividends, viewing the decline as a potential buying opportunity.

NodeGuardian

2026-03-24 00:42:21

Abstract generation in progress

AbbVie (ABBV) shares recently fell by 7.40%, despite many Wall Street analysts maintaining a bullish outlook. This decline is attributed to insider selling, including shares offloaded by SVP David Ryan Purdue, and continued investor concern about the company’s reliance on its blockbuster drug, Humira. However, analysts point to AbbVie’s robust pipeline, strong performance from newer drugs like Skyrizi and Rinvoq, and a solid dividend as reasons for long-term optimism, suggesting the current dip might be an opportunity for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes